Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies

Autor: Kyogo Itoh, Takahisa Shirahama, Tetsuro Sasada, Akira Yamada, Michi Morita, Daisuke Muroya, Rin Yamaguchi, Satoko Matsueda, Shigeki Shichijo, Shigeru Yutani
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
Cancer immunotherapy
Kaplan-Meier Estimate
immune response
Basic and Clinical Immunology
0302 clinical medicine
Precision Medicine
Aged
80 and over
Liver Neoplasms
Vaccination
hepatocellular carcinoma
General Medicine
Middle Aged
Sorafenib
Combined Modality Therapy
Treatment Outcome
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Vaccines
Subunit
Cohort
Female
Original Article
medicine.drug
Adult
Niacinamide
medicine.medical_specialty
Carcinoma
Hepatocellular
overall survival
Antineoplastic Agents
Cancer Vaccines
03 medical and health sciences
Refractory
Internal medicine
Injection site reaction
medicine
Humans
Chemoembolization
Therapeutic
Adverse effect
Aged
business.industry
Phenylurea Compounds
personalized peptide vaccine
Original Articles
medicine.disease
Surgery
Clinical trial
030104 developmental biology
Drug Resistance
Neoplasm
Feasibility Studies
business
T-Lymphocytes
Cytotoxic
Zdroj: Cancer Science
ISSN: 1349-7006
1347-9032
DOI: 10.1111/cas.13301
Popis: Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC, in which the peptides were selected from 31 peptide candidates based on the pre‐existing immunity. Twenty‐six HCC patients refractory to locoregional therapies (cohort 1) and 30 patients refractory to both locoregional and systemic therapies (cohort 2) were entered into the study. There were no severe adverse events related to PPV except for one injection site reaction. At the end of the first cycle of six vaccinations, successful CTL or IgG boosting was observed in 57% or 46% of patients in cohort 1 and in 54% or 52% of patients in cohort 2, respectively. Successful IgG boosting at the end of the second cycle was observed in the majority of patients tested. Median overall survival was 18.7 months (95% confidence interval, 12.2–22.5 months) in cohort 1, and 8.5 months (95% confidence interval, 5.9–12.2 months) in cohort 2. Based on the higher rates of immune boosting and the safety profile of PPV, further clinical studies of PPV would be warranted for patients with HCC refractory to not only locoregional therapy but also both locoregional and systemic therapies. The protocol of this study was registered with the UMIN Clinical Trials Registry (UMIN000001882 and UMIN000003590).
Databáze: OpenAIRE
Externí odkaz: